Higher AIP level was positively and strongly associated with obesity. AIP is a novel and better biomarker associated with obesity. It can be used in clinical practice as a direct biological target to evaluate the effect of hypolipidemic drugs on the prevention and treatment of obesity, which may facilitate clinicians to adjust the medication plan in order to reduce the adverse reactions caused by long-term use of lipid-lowering drugs.

AIP values increase with increasing CV risk. Thus umbilical cord, young children, healthy women have values below 0.1 while men and subjects with CV risk factors such as hypertension, diabetes, dyslipidemia have increasing values up to 0.4. Based on these data we suggest that AIP values of -0.3 to 0.1 are associated with low, 0.1 to 0.24 with medium and above 0.24 with high CV risk.

1) https://www.ijpbs.com/ijpbsadmin/upload/ijpbs_526938e855804.pdf

2) https://lipidworld.biomedcentral.com/articles/10.1186/s12944-018-0686-8#:~:text=Atherogenic%20index%20of%20plasma%20(AIP)%20is%20a%20novel%20index%20composed,7%2C8%2C9%5D.

3) https://pubmed.ncbi.nlm.nih.gov/16526201/